Skip to main content
Journal cover image

How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?

Publication ,  Journal Article
Zaki, IH; Shropshire, E; Zhang, S; Xiao, D; Wildman-Tobriner, B; Marin, D; Gupta, RT; Erkanli, A; Nelson, RC; Bashir, MR
Published in: Abdom Radiol (NY)
March 2021

OBJECTIVE: To determine the rate of development of clinically significant liver nodules (LR-4, LR-5, LR-M) after a negative MRI in an HCC screening population. METHODS: This retrospective study included patients at risk of developing HCC requiring imaging surveillance who had undergone multiphase Gadobenate dimeglumine-enhanced MRI that was negative and had follow up LI-RADS compliant multiphase CTs or MRIs for at least 12 months or positive follow-up within 12 months. Follow-up examinations were classified as negative (no nodules or only LR-1 nodules) or positive (nodule other than LR-1). Time-to-first positive examination, types of nodules, and cumulative incidence of nodule development were recorded. RESULTS: 204 patients (mean age 58.9 ± 10.2 years, 128 women), including 172 with cirrhosis, were included. Based CT/MRI follow-up (median 35 months, range 12-80 months), the overall cumulative incidence of developing a nodule was 10.5%. Cumulative incidence of nodule development was: 0.5% at 6-9 months and 2.1% at 12 ± 3 months, including one LR-4 nodule, one LR-M nodule, and two LR-3 nodules. The cumulative incidence of clinically significant nodule development was 1.1% at 9-15 months. 70% (143/204) of patients also underwent at least one US follow-up, and no patient developed a positive US examination following index negative MRI. CONCLUSION: Clinically significant liver nodules develop in 1.1% of at-risk patients in the first year following negative MRI. While ongoing surveillance is necessary for at-risk patients, our study suggests than longer surveillance intervals after a negative MRI may be reasonable and that further research is needed to explore this possibility.

Duke Scholars

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

March 2021

Volume

46

Issue

3

Start / End Page

969 / 978

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Organometallic Compounds
  • Middle Aged
  • Meglumine
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
  • Female
  • Carcinoma, Hepatocellular
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zaki, I. H., Shropshire, E., Zhang, S., Xiao, D., Wildman-Tobriner, B., Marin, D., … Bashir, M. R. (2021). How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY), 46(3), 969–978. https://doi.org/10.1007/s00261-020-02771-5
Zaki, Islam H., Erin Shropshire, Shuaiqi Zhang, Dong Xiao, Benjamin Wildman-Tobriner, Daniele Marin, Rajan T. Gupta, Alaattin Erkanli, Redon C. Nelson, and Mustafa R. Bashir. “How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?Abdom Radiol (NY) 46, no. 3 (March 2021): 969–78. https://doi.org/10.1007/s00261-020-02771-5.
Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, et al. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY). 2021 Mar;46(3):969–78.
Zaki, Islam H., et al. “How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?Abdom Radiol (NY), vol. 46, no. 3, Mar. 2021, pp. 969–78. Pubmed, doi:10.1007/s00261-020-02771-5.
Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY). 2021 Mar;46(3):969–978.
Journal cover image

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

March 2021

Volume

46

Issue

3

Start / End Page

969 / 978

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Organometallic Compounds
  • Middle Aged
  • Meglumine
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
  • Female
  • Carcinoma, Hepatocellular
  • Aged